Early statin use links to lower dementia risk in diabetes
Early statin initiation was associated with a 15% lower 10-year relative risk of dementia compared to no statin treatment in people with type 2 diabetes.
The Lancet Regional Health Europe
Researchers analyzed nationwide Danish health registers tracking 132,585 statin-naïve adults who developed type 2 diabetes between 2006 and 2019. Using a target trial emulation design, the team compared individuals starting statins within one year of diagnosis, those starting between one and five years, and those who did not start within five years.
Over a median follow-up of 7.1 years, 3,592 individuals developed all-cause dementia. Estimated 10-year absolute dementia risks were 3.9% with no statins, 3.5% with late initiation, and 3.3% with early initiation. Compared to no statin initiation, early statin treatment was associated with a 15% lower relative risk of dementia, while late initiation was associated with a 10% lower relative risk. Absolute risk differences were 0.59% lower for early start and 0.38% lower for late start.
Why it matters
Dementia risk rises alongside aging and metabolic dysfunction, making early intervention on modifiable vascular factors a potential strategy to preserve late-life cognition.
Caveats
The findings come from an observational registry study and show an association, requiring randomized clinical trials to confirm whether early statin initiation directly reduces dementia incidence.
The paper
University of Copenhagen
The Lancet Regional Health Europe · 27 Aug 2026